These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8136088)

  • 1. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.
    Creutzfeldt W
    Drug Saf; 1994 Jan; 10(1):66-82. PubMed ID: 8136088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
    McTavish D; Buckley MM; Heel RC
    Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
    Wilde MI; McTavish D
    Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is hypergastrinaemia dangerous to man?
    Creutzfeldt W; Lamberts R
    Scand J Gastroenterol Suppl; 1991; 180():179-91. PubMed ID: 1675024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with omeprazole in erosive oesophagitis.
    Robinson MG; Decktor DL
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():69-77. PubMed ID: 1679674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
    Hage E; Hendel L; Gustafsen J; Hendel J
    Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole: long-term safety.
    Arnold R; Koop H
    Digestion; 1989; 44 Suppl 1():77-86. PubMed ID: 2691313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
    Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth.
    Creutzfeldt W; Lamberts R
    Digestion; 1992; 51 Suppl 1():76-81. PubMed ID: 1397748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acid-related disorders with gastric acid inhibitors: the state of the art.
    Blum AL
    Digestion; 1990; 47 Suppl 1():3-10; discussion 49-52. PubMed ID: 1982662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy.
    Klinkenberg-Knol EC; Meuwissen SG
    Digestion; 1992; 51 Suppl 1():44-8. PubMed ID: 1356868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole.
    Solcia E; Rindi G; Havu N; Elm G
    Scand J Gastroenterol Suppl; 1989; 166():129-37; discussion 138-9. PubMed ID: 2513643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.
    Bardram L; Thomsen P; Stadil F
    Digestion; 1986; 35 Suppl 1():116-22. PubMed ID: 3792668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole in the short-term treatment of reflux oesophagitis.
    Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():40-6. PubMed ID: 2691310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.